{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-005392","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.250568+00:00","generated_at":"2026-05-18T01:07:27.701528+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phio reports complete response in cSCC and manufacturing agreement for PH-762","bullets":["Entered into comprehensive drug substance development agreement with U.S. manufacturer for PH-762.","Phase 1b fourth-cohort: one complete pathologic response (100% tumor clearance) in cSCC patient.","One partial response (>50% clearance) in stage 4 metastatic Merkel cell; two non-responses in cSCC.","No dose-limiting toxicities; PH-762 well tolerated across all cohorts; no clinical progression.","Enrolling 5th and expected final cohort in Phase 1b dose escalation study for cutaneous carcinomas."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-005392","json":"https://secwatch.observer/filing/0001683168-25-005392.json","markdown":"https://secwatch.observer/filing/0001683168-25-005392.md","text":"https://secwatch.observer/filing/0001683168-25-005392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825005392/0001683168-25-005392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825005392/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T01:07:27.701528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}